The rising global burden of cerebrovascular disease, propelled by an aging population, highlights the inherent limitations of conventional, labor-intensive diagnostic paradigms. In the context of time-sensitive stroke management, variability in image interpretation and the high rate of misclassification, particularly during the assessment of transient ischemic attack (TIA), underscore the urgent need for more consistent and efficient diagnostic solutions. Artificial intelligence (AI), particularly deep learning (DL), offers a transformative pathway by automating the analysis of complex neurovascular imaging. Here, we conduct a comprehensive examination of how DL is revolutionizing stroke-related image analysis, moving beyond general assertions of potential to discuss specific technical implementations. We systematically detail the evolution from traditional segmentation algorithms to advanced deep learning architectures—such as U-Net, DeepMedic, and their variants—in performing critical tasks. These tasks encompass the automated segmentation of intracranial and extracranial (carotid) arteries, the quantification of stenosis and plaque burden, and the hemodynamic assessment of vascular lesions across modalities including MRA, CTA, and DSA. By synthesizing landmark studies, our analysis delineates three core aspects: the technological trajectory of DL models in achieving expert-level accuracy in vascular feature extraction in controlled studies; the clinical translation of these tools into diagnostic, prognostic, or therapeutic procedural planning workflows; and the persistent challenges and future directions, including data standardization, model generalizability, and multimodal integration. This review posits that DL represents not merely an assistive technology but a foundational cornerstone for the next generation of precision cerebrovascular medicine. It holds the potential to bridge critical gaps in diagnostic speed, objectivity, and accessibility, provided its development and validation are guided by rigorous, interdisciplinary collaboration.
ADHD as a disorder of operational capacity: a buffered-state framework for sustained engagement instability
Attention-deficit/hyperactivity disorder (ADHD) is commonly conceptualized as a disorder of executive dysfunction or impaired motivation. In clinical practice, however, many individuals with ADHD describe a different core difficulty: they can initiate tasks appropriately, understand goals, and exert effort, yet struggle to remain engaged as time-on-task and internal strain accumulate. These failures are often abrupt, ego-dystonic, and strongly context-dependent, posing challenges for models based solely on static deficits or gradual depletion. Building on this phenomenology, we propose a constraint-level framework that conceptualizes ADHD as a disorder of operational capacity—the finite tolerance for sustaining stable mental engagement under cumulative cognitive and emotional demand. Within this framework, sustained engagement is modeled as a buffered state that remains stable while cumulative load is within tolerance but becomes increasingly fragile near saturation and may undergo nonlinear collapse into disengagement. We formalize this governing constraint as Operational Economy (OE)—a regulatory, not energetic, constraint principle—and describe a pre-volitional Global Switching Framework (GSF) that mediates rapid state transitions once engagement stability is exceeded. This formulation integrates and extends cognitive-energetic and state-regulation accounts while explicitly differentiating the OE/GSF framework from these predecessors by its emphasis on threshold-dependent dynamics, bounded tolerance, and asymmetric re-engagement. This framework offers a coherent account of clinical features such as intact initial performance with late-stage disengagement, pronounced time-on-task effects, and context-dependent hyperfocus. The framework generates falsifiable predictions regarding sensitivity to cumulative demand, stress-related acceleration of disengagement, pharmacological effects that preferentially extend engagement endurance rather than normalize peak executive performance, and individual differences across ADHD subtypes and comorbid presentations. These predictions are consistent with existing empirical findings on time-dependent variability in ADHD and provide a basis for future experimental validation.
Altered EEG microstate dynamics in adolescents with non-suicidal self-injury at rest and following acute social exclusion
BackgroundNon-suicidal self-injury (NSSI) is highly prevalent in adolescence, yet the fast dynamics of large-scale brain networks remain poorly understood. We aimed to characterize resting-state EEG microstate dynamics in a clinically recruited adolescent NSSI sample and to examine state-dependent changes following acute social exclusion.MethodsResting-state EEG was recorded in hospitalized, medicated adolescents with NSSI and in healthy controls (HCs). An NSSI subgroup then completed EEG assessments before and after either Cyberball-induced social exclusion or a non-stress control condition. Microstate parameters and transition probabilities were analyzed.ResultsAfter multiple-comparison correction, the core baseline finding was robustly reduced microstate A duration in the NSSI group relative to HCs. In uncorrected exploratory analyses, additional differences included shorter durations of microstates B and F, higher occurrence of microstate D, and increased F→D transition probability. A multivariate pattern analysis suggested group-related information but must be interpreted cautiously given the modest sample size. Within the NSSI group, the exclusion group showed reduced microstate A expression and increased microstate D expression relative to the non-stress subgroup, with a broader transition shift toward microstate D. Several interaction effects survived correction.ConclusionsIn this medicated inpatient sample, resting-state microstate dynamics differed from HCs, most robustly in reduced microstate A duration, and reorganized after social exclusion. Specificity to NSSI remains uncertain given the absence of an MDD-only clinical-control group and healthy Cyberball comparison. These preliminary findings require replication in larger studies including medication-naive MDD-only, MDD+NSSI, and HC groups.
Fragile self, mechanical world: mechanistic delusions and ego fragility in schizotypal–affective spectrum disorder—a CARE case report
Categorical nosological systems frequently fall short when confronted with patients whose presentations cross established diagnostic boundaries. We report M.S., a 44-year-old Brazilian man involuntarily admitted to a psychiatric inpatient unit who presented with systematized persecutory ideation of mechanistic–technological content (chip implantation, satellite-based surveillance), structural ego fragility, absent insight, and progressive social and occupational deterioration. While prior diagnoses of bipolar disorder and provisional schizophrenia had been considered, neither fully captured the clinical complexity. Psychopathological-dimensional analysis, grounded in phenomenological observation and contemporary psychopathological theory, suggests three potentially interacting axes: (1) structural ego fragility (Ich-Schwäche), potentially arising from impaired early attachment and deficient relational learning; (2) a relational causality deficit replaced by concrete–mechanistic reasoning; and (3) limbic hyperactivation that appears to sustain an anxiety–perplexity–paranoia feedback loop. These converge on a schizotypal–affective spectrum formulation. Laboratory investigations identified severe dyslipidemia and marked hyperandrogenism (total testosterone 1,367 ng/dL), the latter potentially associated with limbic hyperactivation, though causality cannot be established from a single cross-sectional measurement. Psychometric assessment (BPRS-18) at admission yielded a total score of 43, with suspiciousness (5) and unusual thought content (5) as dominant items. During a seven-day inpatient course, a multimodal thymic strategy—risperidone, lithium carbonate, and structured psychotherapy—produced attenuation of paranoid reactivity, improved family engagement, and the spontaneous resumption of guitar playing from day 3, as a functional correlate of behavioral stabilization. The patient was discharged with a referral for a three-monthly paliperidone palmitate long-acting injectable. The pharmacological response retrospectively supports the dimensional formulation and illustrates the heuristic value of psychopathological analysis grounded in ego structure, causal reasoning, and affective dysregulation as a complementary approach to categorical nosology in complex psychotic–affective presentations.
Editor’s pick: Stylus Medicine
Nature Biotechnology, Published online: 16 July 2026; doi:10.1038/s41587-026-03225-x
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Stylus Medicine is engineering novel recombinases for in vivo CAR T cell cancer therapy.
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial
Nature Medicine, Published online: 16 July 2026; doi:10.1038/s41591-026-04533-0
Combining the CD19–4-1BBL co-stimulatory molecule englumafusp alfa with the bispecific antibody glofitamab in patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma showed acceptable safety signals and encouraging preliminary clinical responses, with mechanistic data supporting the rational choice of therapy.
STAT+: Spring forward forever? Another daylight saving debate arrives in Congress
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Who are you rooting for in the World Cup final? Personally, I’m hoping for more drama and heartbreak, plus a good seat wherever I’m watching.
Trump health nominees face fire at Senate hearing
The Senate health committee held a hearing yesterday, and STAT’s Chelsea Cirruzzo was there in person following along:
Parkinson’s Drug Candidate Enhances Levodopa Therapy While Reducing Side Effects
Scientists have identified a compound that could improve the benefits of levodopa treatment for patients with Parkinson’s disease while delaying or preventing side effects that commonly develop with long-term use. The discovery was made at Sinopia Biosciences, a spinout of the University of California San Diego that analyzes large biological datasets to identify novel therapeutic approaches for preventing and managing side effects of existing drugs.
Preclinical findings published today in Science Translational Medicine suggest the drug candidate could significantly enhance the performance of the most effective and widely used treatment for Parkinson’s. If confirmed in clinical trials, the approach could represent a major advancement in the treatment of this increasingly prevalent neurodegenerative condition.
Levodopa can dramatically improve Parkinson’s symptoms, especially during the early stages of the disease. Over time, however, its effects start wearing off between doses, and within five years of treatment, about 40% of patients develop dyskinesia—a complication involving erratic and involuntary movements. Amantadine is currently the only approved drug to treat dyskinesia induced by levodopa, but its psychiatric and vascular side effects significantly limit its use.
“Virtually every Parkinson’s patient takes levodopa,” said Aarash Bordbar, PhD, chief executive officer, chief scientific officer and co-founder of Sinopia Biosciences. “But patients face two major problems with the drug: the reappearance of Parkinson’s symptoms and dyskinesia. There is no drug that can be added to levodopa to address both simultaneously in a robust manner, and that’s what our drug candidate is doing.”
Bordbar’s team analyzed transcriptomics data to understand how levodopa changes gene expression patterns in the striatum, a brain region involved in movement control. The results were compared with a dataset of gene expression changes induced by existing drugs, allowing the researchers to identify compounds that activated the same transcriptional programs responsible for levodopa’s motor benefits while opposing gene expression programs linked to dyskinesia side effects.
“Maximizing clinical benefits of therapeutics while minimizing adverse effects is a central challenge in drug development,” said Bordbar. “By focusing on the pharmacology of an effective drug rather than disease biology alone, the approach prioritizes pathways with demonstrated clinical relevance, increasing translational potential.”
The team identified a promising candidate in trapidil, a drug that has been used for over 50 years in Japan to treat angina. The drug targets PKA-III, a protein involved in movement and dopamine responses within the brain. The researchers then designed a new compound based on trapidil and tested it in mouse and macaque models of Parkinson’s disease.
Results showed that the drug candidate could offer a dual benefit to Parkinson’s patients, simultaneously improving the motor benefits of levodopa while delaying or preventing treatment-related complications—potentially benefiting both long-term users and patients who are newly starting levodopa therapy.
Based on these findings, Bordbar believes there’s a high chance Sinopia’s drug candidate will succeed in clinical trials. This is further supported by the fact the compound is based on a drug that has been safely used for decades. The company is currently completing the toxicology studies required ahead of the first-in-human clinical trial, which is expected to begin next year.
The post Parkinson’s Drug Candidate Enhances Levodopa Therapy While Reducing Side Effects appeared first on Inside Precision Medicine.
Weekly Digital Symptom Check-Ins Improve Outcomes for Cancer Patients
A study by the Alliance for Clinical Trials in Oncology has shown that completing a simple weekly electronic symptom check-in significantly improves quality of life and may reduce health disparities among people undergoing treatment for advanced cancer.
The PRO-TECT study, which is published in JCO Oncology Practice, showed that the biggest improvements occurred among patient groups that have historically faced greater symptom burden or barriers to effective communication with their care team, including Black patients, women, younger patients, and individuals with less formal education.
“Although we know from prior work that systematic symptom monitoring improves quality-of-life outcomes in patients with advanced cancer, the current analysis extends these findings by suggesting that some groups may experience greater benefit,” said first author Allison Deal, MS, a senior biostatistician at the UNC Lineberger Comprehensive Cancer Center.
Study chair Ethan Basch, MD, who is also from the UNC Lineberger Comprehensive Cancer Center explained that the use of remote symptom monitoring using patient-reported outcomes (PROs) in cancer care in increasing across the U.S., with more than 80 health systems and large practices currently implementing this approach. However, he added that “this is still an early time for this patient-centered approach to monitoring patients, and many practices are still learning how best to implement at their own sites.”
For the PRO-TECT study, 1191 adult patients with metastatic solid tumors receiving systemic therapy were randomly assigned to complete weekly electronic symptom monitoring (n=593) or usual care (n=598) for up to one year.
The weekly surveys included questions about symptoms from the National Cancer Institute’s PRO version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library, oral intake, patient-reported performance status, and falls. The surveys took a few minutes to complete and patients could choose whether to complete them online (64%) or via telephone-based interactive voice response not requiring Internet access (36%).
If the answers passed a prespecified threshold (i.e., severity or worsening from previous assessment), the participant was sent a link to relevant patient-level materials for self-management of the reported symptom, and a nurse on the participant’s clinical care team was sent an automated email alert.
The researchers report that, during the study, 90% of surveys were completed and 41% of reports triggered an alert.
At three months, participants in the PRO arm had a mean 2.37-point improvement, from a baseline of 77.0 points, in the European Organisation for Research and Treatment of Cancer QLQ-C30 symptom control score, and a mean 1.54-point improvement, from a baseline of 73.9 points, in physical function score.
By comparison, participants given usual care reported a 0.20- and 0.93-point decline in symptom control and physical function, respectively.
Basch noted that the differences between the two arms were statistically significant and clinically meaningful, adding that there were also “substantial delays until symptom worsening” among people in the PRO arm relative to the usual care arm.
Deal and co-investigators also observed significant differences in outcome by race, education level, age, and sex.
Specifically, they found that the improvement in symptom control in the PRO arm was significantly larger in Black patients than in White patients, which essentially erased a baseline gap and brought symptom control among Black patients on par with that among patients by month 3. Black patients were also much more likely to report that the weekly surveys made them feel more in control of their own care and improved conversations with their care team.
Patients with a high school education or less who used the weekly surveys had significantly greater improvements in both symptom control and physical function than those with a college education. They also had higher rates of triggered alerts and reported that the weekly questions felt relevant to their daily lives.
Women and younger patients (<65 years), two groups that traditionally report higher distress and more severe side effects during cancer treatment, experienced substantial quality-of-life gains from the weekly check-ins compared with the usual care group, whereas men and older patients saw no significant improvement relative to usual care.
In addition, the weekly reporting tool was associated with significantly reduced or delayed emergency department visits for patients, which are known to cause financial and emotional stress for patients and their families.
“Our results suggest that remote monitoring may provide underserved cancer patients with a new avenue to communicate concerns that might go underrecognized in routine practice,” Basch told Inside Precision Medicine. “Broad implementation of these systems may represent an effective and highly practical strategy to advance health equity. Future studies should test technology with more general patient audiences.”
He added: “There is a follow-up initiative to this trial called OncoPRO which is supporting health systems across the country as they work to onboard these systems.”
The post Weekly Digital Symptom Check-Ins Improve Outcomes for Cancer Patients appeared first on Inside Precision Medicine.
STAT+: New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosis
In a new study published in Science Translational Medicine on Wednesday, researchers say they have uncovered how Epstein-Barr virus launches immune responses that lead to the inflammation and nervous system damage seen in people with multiple sclerosis.
“It’s very nice now to be able to understand more about the underlying mechanisms of how EBV likely causes MS,” said lead author Kjetil Bjornevik, an assistant professor of epidemiology and nutrition at the Harvard T.H. Chan School of Public Health. The findings, researchers hope, could help with the development of EBV vaccines or antiviral medications that could prevent or manage MS symptoms without the major side effects of commonly used immunosuppressants.
Syed Rizvi, the director of the Multiple Sclerosis Center of Rhode Island, who was not involved in this study, said the new findings help advance MS research toward more precise approaches. “When you’re developing drugs, targeted drugs, every little step, every little molecule, every little antigen is a game changer,” he said.